Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P61011
UPID:
SRP54_HUMAN
Alternative names:
Signal recognition particle 54 kDa protein
Alternative UPACC:
P61011; B2R759; B4DUW6; P13624
Background:
The Signal recognition particle subunit SRP54, a 54 kDa protein, plays a pivotal role in the cotranslational targeting of secretory and membrane proteins to the endoplasmic reticulum (ER). It is a key component of the signal recognition particle (SRP) complex, facilitating the interaction with the SRP receptor and the subsequent translocation of proteins into the ER. SRP54's GTPase activity is crucial for this process, enabling the dynamic rearrangement necessary for efficient protein targeting.
Therapeutic significance:
SRP54's involvement in severe congenital neutropenia underscores its therapeutic potential. By understanding its role in granulocytic cell proliferation, neutrophil migration, and exocrine pancreas development, novel strategies for treating this hematopoiesis disorder could be developed, offering hope for patients suffering from this condition.